Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke, Charlie Gourley, Amit Oza, Antonio González-martín, Carol Aghajanian, William H Bradley, Eileen Holmes, Elizabeth S Lowe, Paul Disilvestro

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalThe Lancet Oncology
DOIs
Publication statusPublished - 26 Oct 2021

Cite this